Featured Research

from universities, journals, and other organizations

Potential Atherosclerosis Drug Exhibits No Harmful Side-effects In Liver

Date:
February 23, 2009
Source:
American Society for Biochemistry and Molecular Biology
Summary:
Researchers have developed and tested a synthetic atherosclerosis drug that can reduce the build-up of dangerous blood vessel plaques without producing the side-effect of fatty liver disease. The encouraging results of this study in mice could lead to a new type of drug to treat or even prevent atherosclerosis.

Researchers have developed and tested a synthetic atherosclerosis drug that can reduce the build-up of dangerous blood vessel plaques without producing the side-effect of fatty liver disease (which leads to its own set of problems like diabetes). The encouraging results of this study in mice could lead to a new type of drug to treat or even prevent atherosclerosis.

Targets of this drug, called DMHCA, are proteins called the Liver X Receptors (LXR). These proteins control a body's cholesterol levels by limiting the absorption of dietary cholesterol and by increasing the conversion of cholesterol into bile acids. Unfortunately, most LXR ligands also control fatty acid production, so therapeutic compounds that activate LXR also raise the levels of other fats, particularly in the liver.

DHMCA, though, had negligible effects of fat production in laboratory tests, so Dagmar Kratky and colleagues tested it in mice genetically engineered to be atherosclerotic. They found that compared to another experimental LXR drug (T0901317), DMHCA could significantly reduce the size of arterial lesions in the mice (45-48%) without increasing fat content in the liver or blood.

Together, these results, appearing in the February Journal of Lipid Research, show much therapeutic promise.


Story Source:

The above story is based on materials provided by American Society for Biochemistry and Molecular Biology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kratzer et al. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. The Journal of Lipid Research, 2008; 50 (2): 312 DOI: 10.1194/jlr.M800376-JLR200

Cite This Page:

American Society for Biochemistry and Molecular Biology. "Potential Atherosclerosis Drug Exhibits No Harmful Side-effects In Liver." ScienceDaily. ScienceDaily, 23 February 2009. <www.sciencedaily.com/releases/2009/02/090213115024.htm>.
American Society for Biochemistry and Molecular Biology. (2009, February 23). Potential Atherosclerosis Drug Exhibits No Harmful Side-effects In Liver. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2009/02/090213115024.htm
American Society for Biochemistry and Molecular Biology. "Potential Atherosclerosis Drug Exhibits No Harmful Side-effects In Liver." ScienceDaily. www.sciencedaily.com/releases/2009/02/090213115024.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins